Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a 3-day course of therapy with orally
administered VCH-916 given at different dosages can effectively reduce the amount of
circulating virus (i.e., viral load) in patients with early-stage chronic hepatitis
C-infection. This study will also evaluate the safety and tolerability of treatment with
VCH-916. Blood samples will also be taken to measure the levels of VCH-916 present in plasma
at various time points during the treatment period.